#1 Clinical Trials Search in Europe

Study on the Safety and Effectiveness of SLAMF7 CAR-T Cells for Patients with Multiple Myeloma

2 1 1

What is this study about?

This clinical trial is focused on studying a type of blood cancer called multiple myeloma. The study is testing a new treatment using genetically modified cells known as SLAMF7 CAR-T cells. These are special cells taken from the patient’s own body, which are then altered in a lab to help them better fight cancer. The cells are modified to target a specific protein found on the surface of cancer cells, known as SLAMF7, and are then reintroduced into the patient’s body through an injection.

The purpose of this study is to determine if this treatment is safe and effective for patients with multiple myeloma. The study is divided into two phases. In the first phase, the focus is on assessing the safety of the treatment and finding the best dose to use in the second phase. The second phase will evaluate how well the treatment works in reducing the cancer. Participants will receive the treatment and be monitored over time to see how their bodies respond. This includes checking for any side effects and measuring the treatment’s impact on the cancer.

Throughout the study, participants will have regular check-ups to monitor their health and the progress of the treatment. The study aims to provide valuable information on the potential of SLAMF7 CAR-T cells as a treatment option for multiple myeloma, offering hope for improved outcomes in the future. The trial is expected to continue until 2027, allowing researchers to gather comprehensive data on the long-term effects and benefits of this innovative therapy.

1 initial assessment

Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes reviewing medical history and current health status.

A blood test is performed to ensure the absence of pregnancy in female patients of childbearing potential.

2 treatment preparation

Preparation for treatment involves the collection of autologous T-cells from the patient. These cells are then modified in a laboratory to target multiple myeloma cells.

The modified cells are known as SLAMF7 CAR-T cells.

3 treatment administration

The SLAMF7 CAR-T cells are administered through an intravenous infusion. The dosage varies, with options including 3×105 cells/mL, 1×106 cells/mL, 1×104 cells/mL, 1×105 cells/mL, and 3×104 cells/mL.

The infusion is given as a suspension for injection.

4 monitoring and follow-up

After the infusion, regular monitoring is conducted to assess safety and response to treatment. This includes checking for any adverse effects and measuring the effectiveness of the treatment.

Follow-up visits are scheduled at various intervals: Days 1, 3, 7, 10, 14, 21, 28, Weeks 6, 8, 12, and Months 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18, 21, and 24.

5 evaluation of treatment response

The response to the treatment is evaluated using specific criteria for multiple myeloma. This includes measuring the overall response rate and checking for any signs of disease progression.

Patient-reported outcomes are also collected to assess the impact of the treatment on quality of life.

Who Can Join the Study?

  • The patient must sign a form that shows they understand the study and agree to participate.
  • The patient must be at least 18 years old.
  • The patient must be willing and able to follow the study’s rules and requirements.
  • The patient must have been diagnosed with multiple myeloma and have received at least two previous treatments. These treatments should include high-dose chemotherapy with a transplant of their own stem cells, if eligible, and exposure to specific drugs used for this condition.
  • The patient must have at least one measurable sign of the disease, such as a certain level of M-protein in the blood or urine, an abnormal level of free light chains in the blood, a proven plasmacytoma (a type of tumor), or a certain percentage of plasma cells in the bone marrow.
  • The patient can have been treated with an anti-SLAMF7 antibody before.
  • The patient must have a Karnofsky performance status of 60% or higher, which is a way to measure their ability to perform daily activities. If the status is lower due to a specific injury but the patient is otherwise fit, they may still be eligible.
  • Female patients who can have children must have a negative pregnancy test and agree to use effective birth control methods or abstain from heterosexual contact during the study and for one year after treatment. They must also agree not to breastfeed during this time.
  • Male patients must agree to use a condom during sexual contact with a pregnant woman or a woman who can have children for at least one year after treatment, even if they have had a vasectomy.

Who Cannot Join the Study?

  • Patients who have a different condition than multiple myeloma cannot participate. Multiple myeloma is a type of cancer that affects certain cells in the bone marrow.
  • Patients who are not within the specified age range cannot participate. The age range for this trial is typically adults.
  • Patients who are not part of the specified clinical trial group cannot participate. This means the trial is looking for specific characteristics in participants.
  • Both male and female patients are eligible, so gender is not a reason for exclusion.
  • Patients who are considered part of a vulnerable population may not be eligible. A vulnerable population includes groups who might be at higher risk or need special protection.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Udtvaqmmpzaofplbxwvra Wwvlgqyfc Aqf Wuerzburg Germany

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Germany Germany
Not recruiting
22.07.2020

Trial locations

Investigated drugs:

SLAMF7 CAR-T cells are a type of treatment used in this clinical trial for patients with multiple myeloma, a type of blood cancer. These are specially modified cells taken from the patient’s own immune system. They are engineered to better recognize and attack cancer cells. The goal of using SLAMF7 CAR-T cells is to determine if they are safe and effective in treating multiple myeloma by assessing their ability to reduce or eliminate cancer cells in the body.

Multiple Myeloma – Multiple myeloma is a type of blood cancer that affects plasma cells, which are a kind of white blood cell found in the bone marrow. These abnormal plasma cells multiply rapidly, leading to an overproduction of a single type of antibody, which can cause damage to bones, kidneys, and the immune system. As the disease progresses, it can lead to bone pain, fractures, anemia, and increased susceptibility to infections. The accumulation of myeloma cells in the bone marrow can also interfere with the production of normal blood cells. Over time, the disease can cause significant damage to various organs and systems in the body.

Trial ID:
2024-512643-23-00
Protocol code:
CARAMBA-1
NCT ID:
NCT04499339
Trial Phase:
Phase I and Phase II (Integrated) – First administration to humans

Other Trials to Consider

  • A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

    Recruiting

    4 1 1 1
    Investigated drugs:
    France Norway Spain

  • A study testing etentamig alone or with drug combinations in adult patients with multiple myeloma to assess safety and changes in disease activity

    Recruiting

    1 1 1 1
    Investigated drugs:
    Norway